Publication|Articles|December 18, 2024
Supplements and Featured Publications
- Year in Review: Multiple Myeloma
Year in Review: Multiple Myeloma
Listen
0:00 / 0:00
Advertisement
This 2024 multiple myeloma year in review recaps clinical trial data presented at major conferences and important FDA updates, including the April 2024 vote by the Oncologic Drug Advisory Committee that measures of minimal residual disease (MRD) negativity could be part of a surrogate end point in trials.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
5
